Ratings SenzaGen AB

Equities

Delayed Nasdaq Stockholm Other stock markets 07:29:38 2024-05-15 am EDT			5-day change	1st Jan Change
8.96 ^SEK	-5.08%		-5.68%	+23.08%

Mar. 25	Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader	CI
Mar. 22	SenzaGen AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

The prospective high growth for the next fiscal years is among the main assets of the company
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SENZAGEN AB	+23.08%	21.1M		-
EXACT SCIENCES CORPORATION	-27.01%	9.96B		A-
GUARDANT HEALTH, INC.	-8.58%	3.03B		C
IOVANCE BIOTHERAPEUTICS, INC.	+31.86%	3B		D+
BGI GENOMICS CO., LTD.	-13.62%	2.18B	-	B-
VERACYTE, INC.	-16.32%	1.76B		C+
MARAVAI LIFESCIENCES HOLDINGS, INC.	+63.36%	1.42B		B-
CAREDX, INC	+27.00%	794M		C-
SEEGENE, INC.	-2.18%	756M		C+
CURIOX BIOSYSTEMS CO., LTD	+3.18%	305M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality